Everything below concerns Angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
The companies claimed that this machine could peel and cut an avocado in less than 30 seconds and operate unattended on a large batch, which could significantly reduce the time and labor required to prepare large quantities of guacamole. Chipotle's share price fell more than 9% after fiscal second quarter results showed same-store sales shrinking by 4%, compared to 0.4% in the prior quarter. In April 2025, Chipotle announced the opening of a location in Mexico by early 2026, looking to expand into new markets in the region. In August 2025, Chipotle announced plans of delivering food via drone aircraft within the greater Dallas area through a partnership with Zipline. In July 2026, Chipotle opened its first restaurant in Mexico in San Pedro Garza Garcia, Nuevo Leon, in partnership with Alsea. The company planned additional restaurants in Nuevo Leon during 2026 and an expansion into Mexico City in 2027. In August 2026, Chipotle opened its first restaurant in Saudi Arabia, in Riyadh, through a franchise partnership with Alshaya Group. In September 2026, Chipotle opened its first restaurant in South Korea, in the Gangnam District, via a joint venture with SPC Group.
== Chemistry == Edrophonium, ethyl-(3-hydroxyphenyl)dimethylammonium chloride, is made by reacting 3-dimethylaminophenol with ethyl bromide, which forms ethyl(3-hydroxyphenyl)dimethylammonium bromide, the bromine atom of which is replaced with a chlorine atom by reacting it with silver chloride, giving edrophonium.
The saboteur is eventually revealed to be a bird pecking at the console's keyboard, which sends GLaDOS into a panic when she recognizes it as the one who tried to eat her during her time as a potato. ATLAS and P-body manage to shoo away the bird, earning a rare compliment from GLaDOS before she notices eggs in its nest. Instead of having them smashed, GLaDOS has the eggs taken to her chamber so that she can raise the baby birds to be her own little "killing machines". According to GLaDOS, ATLAS and P-body were created for the Cooperative Testing Initiative and were supposed to phase out human testing after Chell escaped with Wheatley. However, she never got around to using them for testing. In the Portal 2 singleplayer campaign, Wheatley finds both ATLAS and P-body in storage and decided to kill both Chell and GLaDOS and use them instead. They later appear when Chell is granted liberty by GLaDOS. Originally, the co-op player characters would be Chell (the single player character), and Mel, another human test subject. This concept was cut when playtesting showed that co-op characters would die a lot. The humans were replaced with infinite respawning robots. During the early phases of Portal 2, ATLAS and P-body's concept showed more of a Westworld feel.
Sources: en.wikipedia.org
leukotriene A4 + glutathione This enzyme belongs to the family of lyases, specifically the class of carbon-sulfur lyases. The systematic name of this enzyme class is leukotriene-C4 glutathione-lyase (leukotriene-A4-forming). Other names in common use include leukotriene C4 synthetase, LTC4 synthase, LTC4 synthetase, leukotriene A4:glutathione S-leukotrienyltransferase, (7E,9E,11Z,14Z)-(5S,6R)-5,6-epoxyicosa-7,9,11,14-tetraenoate:glutathione leukotriene-transferase, (epoxide-ring-opening), (7E,9E,11Z,14Z)-(5S,6R)-6-(glutathion-S-yl)-5-hydroxyicosa-7,9,11,14-tetraenoate glutathione-lyase (epoxide-forming). This enzyme participates in arachidonic acid metabolism.
Despite increased ties to the Latin American left, the Castillo Administration has maintained cordial, if not friendly, relations with the US. Relations began when the US State Department denied Keiko's claims of electoral fraud in the 2021 Peruvian general election. Afterward, relations were further normalized under former Foreign Minister Héctor Béjar, when both countries agreed to hold bilateral meetings every 6 months. Additionally, the US pledged cooperation in vaccines, and aid for the poorest regions of Peru. Relations with the US have been maintained after the resignation of Héctor Béjar. Castillo has also renewed Peru's agreement with USAID for another 5 years. This decision has been protested by a congressman from his party, who accused USAID of being an "accomplice in all the coups in Latin America and a spy agency within our homeland." On 23 October 2021, Castillo gave a speech at the FOLAC 2021, organized by the chambers of commerce of the US and Latin American countries. Castillo stated that "it is a propitious moment to consolidate the strong ties of friendship and cooperation with the United States. We have a new opportunity."
==== Expedition 70/71 ==== Caldwell Dyson returned to flight training as a backup crew member for the Soyuz MS-24. She backed up her NASA astronaut colleague Loral O'Hara. She was officially assigned to the Soyuz MS-25 in 2023. Her first attempt to launch on the Soyuz MS-25 mission on March 21, 2024 was aborted with 20 seconds left before lift-off. The scrub occurred because of a low voltage reading in the Soyuz rocket electrical system. She launched on March 23, 2024 with Roscosmos cosmonaut Oleg Novitsky and Belarusian cosmonaut Marina Vasilevskaya. After a two-day rendezvous profile, the Soyuz crew docked with International Space Station's Prichal module on March 25, 2024. The first weeks of her mission dealt with the SpaceX CRS-30 mission, as well as viewing the total eclipse above North America on April 8, 2024 and the redocking of SpaceX Crew-8 in early May. Starting in mid-May, Expedition 71 crew focused themselves on the preparation for the three planned EVAs. During this period, the crew checked out EMUs, tools, and reviewed procedures. They also performed maintenance tasks around station as well as continued scientific work. On June 6, Caldwell Dyson saw the arrival of the first crewed mission of Starliner. The Starliner crew was composed of Barry Wilmore and Sunita Williams. Caldwell Dyson monitored the arrival of Starliner alongside Matthew Dominick and helped the Starliner crew to accomplish their test flight objectives including testing the spacecraft habitability for four crew members and its capability as a safe haven in case of an emergency.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.